|
Index | - | P/E | - | EPS (ttm) | -2.29 | Insider Own | 0.50% | Shs Outstand | 16.58M | Perf Week | -17.78% |
Market Cap | 72.44M | Forward P/E | - | EPS next Y | -1.84 | Insider Trans | 4.04% | Shs Float | 4.47M | Perf Month | -21.51% |
Income | -32.50M | PEG | - | EPS next Q | -0.45 | Inst Own | 4.00% | Short Float | 1.91% | Perf Quarter | -33.97% |
Sales | 0.00M | P/S | - | EPS this Y | 89.20% | Inst Trans | -8.22% | Short Ratio | 1.95 | Perf Half Y | -47.83% |
Book/sh | 4.57 | P/B | 0.95 | EPS next Y | 12.40% | ROA | -27.10% | Target Price | - | Perf Year | -65.67% |
Cash/sh | - | P/C | - | EPS next 5Y | - | ROE | -42.70% | 52W Range | 4.00 - 12.00 | Perf YTD | -15.69% |
Dividend | - | P/FCF | - | EPS past 5Y | 64.30% | ROI | -28.20% | 52W High | -63.96% | Beta | -0.08 |
Dividend % | - | Quick Ratio | 3.80 | Sales past 5Y | -41.30% | Gross Margin | - | 52W Low | 8.12% | ATR | 0.34 |
Employees | 31 | Current Ratio | 3.80 | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 21.18 | Volatility | 9.04% 5.39% |
Optionable | No | Debt/Eq | 0.24 | EPS Q/Q | 18.10% | Profit Margin | - | Rel Volume | 3.50 | Prev Close | 4.94 |
Shortable | Yes | LT Debt/Eq | 0.23 | Earnings | - | Payout | - | Avg Volume | 43.84K | Price | 4.32 |
Recom | 1.00 | SMA20 | -20.01% | SMA50 | -21.23% | SMA200 | -34.87% | Volume | 153,389 | Change | -12.45% |
![]() | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Windtree Therapeutics, Inc., a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
open in yahoo | open in reuters | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite